{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:06:27Z","timestamp":1748469987367,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejca.2017.11.007","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T18:39:59Z","timestamp":1512758399000},"page":"149-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Positron emission tomography\/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-5092","authenticated-orcid":false,"given":"Viola","family":"Franke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernies","family":"van der Hiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A.","family":"van de Wiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem M.C.","family":"Klop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"ter Meulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ejca.2017.11.007_bib1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.11.007_bib2","first-page":"11","article-title":"Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma","volume":"3","author":"Hughes","year":"2014","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.ejca.2017.11.007_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.11.007_bib4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/fon.10.66","article-title":"OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma","volume":"6","author":"Kaufman","year":"2010","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.11.007_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2017.11.007_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","article-title":"The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy","volume":"44","author":"Wong","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ejca.2017.11.007_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/RLU.0000000000001456","article-title":"FDG-pet\/CT for monitoring response of melanoma to the novel oncolytic viral therapy talimogene laherparepvec","volume":"42","author":"Covington","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"26","key":"10.1016\/j.ejca.2017.11.007_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2017.11.007_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2017.11.007_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.11.007_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-016-0116-2","article-title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","volume":"4","author":"Kaufman","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"34","key":"10.1016\/j.ejca.2017.11.007_bib12","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.11.007_bib13","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.2147\/OTT.S115245","article-title":"Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB\/C and IVM1a melanoma: subanalysis of the phase III OPTiM trial","volume":"9","author":"Harrington","year":"2016","journal-title":"OncoTargets Ther"},{"issue":"2","key":"10.1016\/j.ejca.2017.11.007_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2214\/AJR.14.13575","article-title":"(18)F-FDG PET\/CT and melanoma: staging, immune modulation and mutation-targeted therapy assessment, and prognosis","volume":"205","author":"Perng","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"23","key":"10.1016\/j.ejca.2017.11.007_bib15","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2017.11.007_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","article-title":"Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety","volume":"15","author":"Moreno-Ramirez","year":"2010","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.ejca.2017.11.007_bib17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2017.11.007_bib18","first-page":"122S","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"2","key":"10.1016\/j.ejca.2017.11.007_bib19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T16:27:42Z","timestamp":1573489662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917314041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":19,"alternative-id":["S0959804917314041"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.11.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron emission tomography\/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}